Brainomix said today that it raised nearly $10 million for the e-ASPECTS stroke imaging technology it’s developing using artificial intelligence.
The £7 million round was led by Parkwalk Advisors, joined by existing backers Chimera Partners and Oxford University Innovation Fund and the venture arm of pharma giant Boehringer Ingelheim.
Oxford, England-based Brainomix said its tech is designed to automate the evaluation of stroke patients using CT scan data and the Alberta Stroke Program Early CT Score method. The funds are earmarked for commercializing e-ASPECT, the company said.
“We welcome Boehringer Ingelheim Venture Fund to our team of investors. Their tremendous expertise and heritage in stroke will complement the knowledge of our existing investors. Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries. With this investment we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials,” CEO Michalis Papadakis said in prepared remarks.
“Brainomix is a cutting-edge technology company with superior expertise in innovative stroke care. We are very pleased to join the accomplished management team and this prestigious group of investors. We are looking forward to working with them on breakthrough improvements in stroke care. Their e-ASPECTS solution significantly supports physicians in the demanding acute care setting and is a step forward for fast and consistent stroke diagnosis,” added BIVF managing director Dr. Frank Kalkbrenner.
($1 = £0.711957)
